ReviewMolecules (Basel, Switzerland)2020
Mass Spectrometry Advances and Perspectives for the Characterization of Emerging Adoptive Cell Therapies.
Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Review
- Microfluidics enabled multi-omics triple-shot mass spectrometry for cell-based therapies.Biomicrofluidics · 2024Article
- Advancing CAR T cell therapy through the use of multidimensional omics data.Nature reviews. Clinical oncology · 2023Review
- The ratio of nicotinic acid to nicotinamide as a microbial biomarker for assessing cell therapy product sterility.Molecular therapy. Methods & clinical development · 2022Article
- A Sensitive and Controlled Data-Independent Acquisition Method for Proteomic Analysis of Cell Therapies.Journal of proteome research · 2022Article
- Sample-to-analysis platform for rapid intracellular mass spectrometry from small numbers of cells.Lab on a chip · 2021Article
- Review
- An overview of multiplexed analyses of CAR T-cell therapies: insights and potential.Expert review of proteomics · 2021Article
- Optical chemosensors for the detection of proximally phosphorylated peptides and proteins.RSC chemical biology · 2021Review
- An Analysis of Monitoring Solutions for CAR T Cell Production.Healthcare technology lettersReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adoptive cell therapy is an emerging anti-cancer modality, whereby the patient's own immune cells are engineered to express T-cell receptor (TCR) or chimeric antigen receptor (CAR). CAR-T cell therapies have advanced the furthest, with recent approvals of two treatments by the Food and Drug Administration of Kymriah (trisagenlecleucel) and Yescarta (axicabtagene ciloleucel). Recent developments in proteomic analysis by mass spectrometry (MS) make this technology uniquely suited to enable the comprehensive identification and quantification of the relevant biochemical architecture of CAR-T cell therapies and fulfill current unmet needs for CAR-T product knowledge. These advances include improved sample preparation methods, enhanced separation technologies, and extension of MS-based proteomic to single cells. Innovative technologies such as proteomic analysis of raw material quality attributes (MQA) and final product quality attributes (PQA) may provide insights that could ultimately fuel development strategies and lead to broad implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.